US 20030118985A1
· Hunt et al.
· 2003
[cited by applicant]
AU 2013288641A1
· 2014
[cited by applicant]
CN 1227610A
· 1999
[cited by applicant]
WO WO199746697
· 1997
[cited by applicant]
WO WO2011038290
· 2011
[cited by applicant]
WO WO2011046623
· 2011
[cited by applicant]
WO WO2012040562
· 2012
[cited by applicant]
WO WO2012079000
· 2012
[cited by applicant]
WO WO2012154312
· 2012
[cited by applicant]
WO WO2012158948
· 2012
[cited by applicant]
WO WO2013016468
· 2013
[cited by applicant]
WO WO2013086533
· 2013
[cited by applicant]
WO WO2013090644
· 2013
[cited by applicant]
WO WO2013126726
· 2013
[cited by applicant]
WO WO2013142324
· 2013
[cited by applicant]
WO WO2013163427
· 2013
[cited by applicant]
WO WO2014043386
· 2014
[cited by applicant]
WO WO2015103549
· 2015
[cited by applicant]
Barouch et al., “A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates,”
[cited by applicant]
Brentjens et al., “Treatment of Chronic Lymphocytic Leukemia with Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial.”
[cited by applicant]
Brown et al., “Tolerance of Single, but not Multiple, Amino Acid Replacements in Antibody VH CDR 2: A Means of Minimizing B Cell Wastage from Somatic Hypermutation?”
[cited by applicant]
Clark and Walsh, “Crystal Structure of a 3B3 Variant—A Broadly Neutralizing HIV-1 scFv Antibody,”
[cited by applicant]
Craig et al., “Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates,”
[cited by applicant]
Diskin et al., “Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design,”
[cited by applicant]
Dondelinger et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,”
[cited by applicant]
Gardner et al., “AAV-Expressed eCD4-Ig Provides Durable Protection from Multiple SHIV Challenges,”
[cited by applicant]
GenBank Sequences AFQ31504 (heavy Chain) and AFQ3150 (light chain), Jun. 2012.
[cited by applicant]
Georgiev et al., “Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization,”
[cited by applicant]
Grupp et al., “Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia,”
[cited by applicant]
Han et al., “Chimeric Antigen Receptor-Engineered T Cells for Cancer Immunotherapy: Progress and Challenges,”
[cited by applicant]
Haynes et al., “Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies,”
[cited by applicant]
Huang et al., “Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth,”
[cited by applicant]
Huang et al., “Isolation of Human Monoclonal Antibodies from Peripheral Blood B Cells,”
[cited by applicant]
Jianhua et al., “Modification in Framework Region I Results in a Decreased Affinity of Chimeric Anti-TAG72 Antibody,”
[cited by applicant]
Johnson et al., “Vector-Mediated Gene Transfer Engenders Long-Lived Neutralizing Activity and Protection Against SIV Infection in Monkeys,”
[cited by applicant]
Julg et al., “Virological Control by the CD4-Binding Site Antibody N6 in SHIV-Infected Rhesus Monkeys,”
[cited by applicant]
Klein et al., “Broad Neutralization by a Combination of Antibodies Recognizing the CD4 Binding Site and a New Conformational Epitope on the HIV-1 Envelope Protein,”
[cited by applicant]
Kwong et al., “Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies,”
[cited by applicant]
Kwong et al., “Broadly Neutralizing Antibodies and the Search for an HIV-1 Vaccine: The End of the Beginning,”
[cited by applicant]
Li et al., “Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies,”
[cited by applicant]
Li et al., “Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01,”
[cited by applicant]
Lynch et al., “HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies,”
[cited by applicant]
Lynch et al., “The Development of CD4 Binding Site Antibodies During HIV-1 Infection,”
[cited by applicant]
Matthews et al., “Prospects for Development of a Vaccine Against HTLV-III-Related Disorders,”
[cited by applicant]
Morgan et al., “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2,”
[cited by applicant]
Nakamura et al., “Coverage of Primary Mother-to-Child HIV Transmission Isolates by Second-Generation Broadly Neutralizing Antibodies,”
[cited by applicant]
Neith, “Building Better HIV Antibodies,” Caltech Media Relations, published Oct. 27, 2011, available at http://www.caltech.edu/article/13468 (last accessed May 28, 2013).
[cited by applicant]
Park et al., “Treating Cancer with Genetically Engineered T Cells,”
[cited by applicant]
Rudicell et al., “Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection Against Lentiviral Infection In Vivo,”
[cited by applicant]
Scheid et al., “Sequence and Structural Convergence of Broad and Potent HIV Antibodies that Mimic CD4 Binding,”
[cited by applicant]
Till et al., “Adoptive Immunotherapy for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Using Genetically Modified Autologous CD20-Specific T Cells,”
[cited by applicant]
Tiller et al., “Efficient Generation of Monoclonal Antibodies from Single Human B Cells by Single Cell RT-PCR and Expression Vector Cloning,”
[cited by applicant]
Walker et al., “Mapping Broadly Neutralizing Antibody Specificities in Donor Sera,” AIDS Vaccine 2010, Atlanta Georgia (2010), available at: http://www.vaccineenterprise.org/conference_archive/2010/pdf-presentations/Thu…
[cited by applicant]
West et al., “Structural Basis for Germ-Line Gene Usage of a Potent Class of Antibodies Targeting the CD4-Binding Site of HIV-1 gp120,”
[cited by applicant]
Wu et al., “Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing,”
[cited by applicant]
Wu et al., “Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1,”
[cited by applicant]
Wu et al., “Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site,”
[cited by applicant]
Zalevsky et al., “Enhanced Antibody Half-Life Improves In Vivo Activity,”
[cited by applicant]
Zhao et al., “Study of HIV-1 gpl20 monoclonal antibody blocking HIV infection of CD4 lymphocyte in vitro experiment,”
[cited by applicant]
Zhou et al., “Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01,”
[cited by applicant]
Zhou et al., “Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies,”
[cited by applicant]
Zhu et al., “De Novo Identification of VRC01 Class HIV-1-Neutralizing Antibodies by Next-Generation Sequencing of B-Cell Transcripts,”
[cited by applicant]